May 7, 2020

prpdp-LevETIRAcetam Oral Solution 100 mg/mL now available in Canada

Print

PENDOPHARM, a division of Pharmascience Inc. is proud to announce the launch of prpdp-LevETIRAcetam Oral Solution 100 mg/mL. 

prpdp-LevETIRAcetam will be the first oral solution of this antiepileptic agent with a Health Canada approved indication for the pediatric population. prpdp-LevETIRAcetam Oral Solution is indicated as adjunctive therapy in the treatment of:

  • Partial onset seizures with or without secondary generalization in adolescents, children and infants, from one month of age, who have epilepsy; 
  • Myoclonic seizures, in adolescents, from the age of 12 years, who have juvenile myoclonic epilepsy; 
  • Primary generalized tonic-clonic seizures, in adolescents, from the age of 12 years, who have generalized idiopathic epilepsy.

prpdp-LevETIRAcetam Oral Solution is the preferred formulation over tablets for use in infants and children under the age of 6 years, and in any patients unable to swallow tablets.

In Canada, each year an average of 15,500 people discover they have epilepsy and 44% are diagnosed before the age of 5.1

“Canadian pediatric patients have been lacking an approved oral solution for the treatment of seizures with a favourable safety profile,” Jean-François Lemieux, Vice President and General Manager, PENDOPHARM, explains, “Canadian infants and children will be able to benefit from a new route of administration for the most prescribed antiepileptic drug in our country.2 prpdp-LevETIRAcetam Oral Solution covers the broadest spectrum of seizures and offers a favourable pharmacokinetic profile.”

“Pharmascience is proud to offer new pediatric formulations to treat serious diseases affecting children. Canada’s health care system has come a long way in terms of the availability of pediatric formulations. However, it continues to lag in comparison to other industrialized countries,” added David Goodman, President and CEO, Pharmascience Inc., “We must adapt our drug approval and reimbursement system, so more manufacturers are encouraged to introduce new pediatric formulations to help children and their caregivers. We must close this gap.”

The oral solution of prpdp-LevETIRAcetam is the third product that PENDOPHARM is launching in this area, having introduced two other products to its range of pediatric products last year. 

About Pharmascience Inc.

Founded in 1983, Pharmascience Inc. is the largest pharmaceutical employer in Quebec with 1,500 employees proudly headquartered in Montreal. Pharmascience Inc. is a full-service privately owned pharmaceutical company with strong roots in Canada and a growing global reach with product distribution in over 60 countries. Ranked 51st among Canada’s top 100 Research & Development (R&D) investors with over $43 million invested in 2018, Pharmascience Inc. is the 4th largest manufacturer generic drugs in the country.

Pharmascience Inc. is a leading manufacturer and marketer of prescription generic, over-the-counter, and behind-the-counter products as well as FDA approved Canadian-made injectables. The company commercializes nearly 300 product families in 20 different dosage forms for over 2,000 products. In Canada alone, more than 45 million prescriptions a year are filled with Pharmascience products. For more information, please visit 

www.pharmascience.com. 

For important information, please refer to the Product Monograph at the following link https://pdf.hres.ca/dpd_pm/00052139.PDF or also available by calling 1-888-550-6060.

For any questions about the oral solution of prpdp-LevETIRAcetam 100mg/mL, please contact the PENDOPHARM Medical Information Department at 1-888-550-6060 or medinfo@pendopharm.com.

  1. Epilepsy Canada. Epilepsy Facts. Accessed online on April 13th, 2020 from URL: https://www.epilepsy.ca/epilepsy-facts.html
  2. IMS Data. Data from October 1, 2018 to September 30, 2019.